AL
Insider
ARCH Venture Partners XII, LLC
10% ownerARCH Venture Partners XII, LLC (10% owner) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (2 purchases, 0 sales), most often in City Therapeutics, Inc. (CTY). Across 1 priced purchase filing, the average 21-session return was -10.2% from execution and -10.2% from disclosure (delay-adjusted; derived). The largest single filing was $19.8M of SPTX (1,100,000 sh × $18.00, as filed), executed May 4. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-10.2%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-10.2%
same 1 filings, from disclosure
Filings, ttm
2
2 buys · 0 sells
Median delay
0d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$22.9M
shares × price, as filed
Last traded
Oct 19
Filed Oct 19
Median ADV $6.4M across their filed names
50% of their measured filings could not be priced (delisted or unquoted names). The returns above cover only what still trades.
Open performance→Volume by month
Buys $37.9M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 12 months
Most traded names
CTYRecent filings
CTYPURCHASE
City Therapeutics, Inc.
View filing →
$3.1M170,000 sh × $18.00
Exec Oct 19
Filed Oct 19 · 5:38 PM ET SPTXPURCHASE Seaport Therapeutics, Inc. View filing → $19.8M
1,100,000 sh × $18.00
Exec May 4
Filed May 4 · 6:02 PM ET NMRAPURCHASE Neumora Therapeutics, Inc. View filing → $5.0M
1,915,700 sh × $2.61
Exec Oct 27 2025
Filed Oct 29 2025 · 7:21 PM ET PRMEPURCHASE Prime Medicine, Inc. View filing → $10.0M
3,030,300 sh × $3.30
Exec Aug 1 2025
Filed Aug 1 2025 · 7:19 PM ET